Israel - English - Ministry of Health

cts ltd - ulipristal acetate - tablets - ulipristal acetate 30 mg - ulipristal - emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

Israel - English - Ministry of Health

cts ltd - ulipristal acetate - tablets - ulipristal acetate 30 mg - ulipristal - emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nuvista pharma ltd - ulipristal acetate - tablet - 30 mg

Malta - English - Medicines Authority

sumar pharma ehf haukahlijð 5 102 reykjavik, iceland - ulipristal acetate - tablet - ulipristal acetate 5 mg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

aspen healthcare malta limited 89, level 0 triq is-siggiewi siggiewi, sgw 2021, , malta - ulipristal acetate - film-coated tablet - ulipristal acetate 30 mg - sex hormones and modulators of the genital system

European Union - English - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - contraception, postcoital - sex hormones and modulators of the genital system, , emergency contraceptives - emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

United States - English - NLM (National Library of Medicine)

hra pharma america, inc. - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . ella is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s. background rate for miscarriage.  in the u.s. general population, the estimated background risk of major birth defects and m

United States - English - NLM (National Library of Medicine)

cenexi hsc - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see  data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar

United States - English - NLM (National Library of Medicine)

redpharm drug, inc - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see  data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar

Canada - English - Health Canada

laboratoire hra pharma - ulipristal acetate - tablet - 30mg - ulipristal acetate 30mg - contraceptives